Search
Lyra Therapeutics Inc
LYRAAdd to Watchlist
0.495USD
0.0000.00%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
1.26MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
0.00%
1 Month
0.00%
6 Months
-84.34%
Year to Date
-83.93%
1 Year
-94.50%
Key Figures
--Open
0.000High
0.00Volume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
11.26%Turnover Ratio
0.495Prev. Close
0.000Low
0.00Turnover
LossP/E Static
3.78P/B
0.00%Div Yield TTM
-53.81%ROA
37.50052wk High
132.39Volume Ratio
-93.44MNet Profit
12.40MShares
-23.1562EPS TTM
-0.09Beta
-404.48%ROE
0.90652wk Low
63.80%Amplitude
100.00%Gross Margin
1.26MMarket Cap
-0.73Reward/Risk
6.89%Risk Rate
TradingKey Stock Score of Lyra Therapeutics Inc
Currency: USD Updated: 2026-03-16Key Insights
Lyra Therapeutics Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 190 out of 393 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 16.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Lyra Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Lyra Therapeutics Inc Highlights
StrengthsRisks
Lyra Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The Company is developing therapies for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210, the Company’s lead product, is a bioabsorbable nasal implant designed to be administered in a simple, in-office procedure and is intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS with a single administration. LYR-210, being evaluated in the ENLIGHTEN Phase III clinical program, is intended for patients with and without nasal polyps. The drug embedded within LYR-210 is mometasone furoate (MF).
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.53M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 1.53M.
Overvalued
The company’s latest PE is -0.02, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 367.19K shares, decreasing 65.70% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 110.00 shares of this stock.
Analyst Rating
Based on
0
analysts
--
Current Rating
16.000
Target Price
+3132.32%
Upside Space
Lyra Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Lyra Therapeutics Inc Info
Lyra Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The Company is developing therapies for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210, the Company’s lead product, is a bioabsorbable nasal implant designed to be administered in a simple, in-office procedure and is intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS with a single administration. LYR-210, being evaluated in the ENLIGHTEN Phase III clinical program, is intended for patients with and without nasal polyps. The drug embedded within LYR-210 is mometasone furoate (MF).
Ticker SymbolLYRA
CompanyLyra Therapeutics Inc
CEOPalasis (Maria)
Websitehttps://lyratherapeutics.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Lyra Therapeutics Inc (LYRA)?
The current price of Lyra Therapeutics Inc (LYRA) is 0.49.
What is the symbol of Lyra Therapeutics Inc?
The ticker symbol of Lyra Therapeutics Inc is LYRA.
What is the 52-week high of Lyra Therapeutics Inc?
The 52-week high of Lyra Therapeutics Inc is 37.50.
What is the 52-week low of Lyra Therapeutics Inc?
The 52-week low of Lyra Therapeutics Inc is 0.91.
What is the market capitalization of Lyra Therapeutics Inc?
The market capitalization of Lyra Therapeutics Inc is 1.26M.
What is the Earnings Per Share (EPS TTM) of Lyra Therapeutics Inc (LYRA)?
The Earnings Per Share (EPS TTM) of Lyra Therapeutics Inc (LYRA) is -18.62.